Study published in the Journal of the American Society of Nephrology (JASN) indicates that long-term PPI use increases the risk of CKD by 28% compared to histamine H2 receptor blockers (Pepcid, Tagamet, Zantac).
Study published in the Journal of the American Society of Nephrology (JASN) indicates that long-term PPI use increases the risk of CKD by 28% compared to histamine H2 receptor blockers (Pepcid, Tagamet, Zantac).